Mortality benefit from unrestricted access to clopidogrel: Too good to be true?

被引：2

|

作者：

Suissa, Samy ^{[1
,2
]}

机构：

[1] McGill Univ, Pharmacoepidemiol Res Unit, Royal Victoria Hosp, Div Clin Epidemiol,Hlth Ctr, Montreal, PQ H3A 1A1, Canada

[2] McGill Univ, Dept Epidemiol & Biostat, Montreal, PQ, Canada

来源：

CANADIAN MEDICAL ASSOCIATION JOURNAL | 2008年 / 178卷 / 04期

关键词：

D O I：

10.1503/cmaj.071592

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

收藏

页码：425 / 427

页数：3

相关论文

共 50 条

[1] Is the Mortality Benefit With Empagliflozin in Type 2 Diabetes Mellitus Too Good To Be True?
Kaul, Sanjay
[J]. CIRCULATION, 2016, 134 (02) : 94 - +
[2] Stopping trials early for benefit: too good to be true
不详
[J]. LANCET, 2008, 371 (9621): : 1310 - 1310
[3] ?Not Too Good to be True?: A Proposal to Further Benefit from Emergence in Management Research
Adrot, Anouck
[J]. MANAGEMENT, 2023, 26 (01): : 85 - 94
[4] No, it is not too good to be true
Kravdal, Oystein
[J]. PAEDIATRIC AND PERINATAL EPIDEMIOLOGY, 2021, 35 (06) : 779 - 780
[5] Too Good to Be True
Jorgensen, Kirsten
Schorge, John O.
[J]. OBSTETRICS AND GYNECOLOGY, 2020, 135 (06): : 1267 - 1269
[6] Too Good to be True?
Sebastian, Martin
Stratmann, Jan Alexander
Eberhardt, Wilfried E. E.
[J]. JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (04) : 507 - 508
[7] Too good to be true
不详
[J]. FORTUNE, 2001, 144 (03) : 25 - 25
[8] TOO GOOD TO BE TRUE?
Birger, Jon
[J]. FORTUNE, 2012, 165 (01) : 35 - 35
[9] TOO GOOD TO BE TRUE
不详
[J]. NEW STATESMAN & SOCIETY, 1989, 2 (43): : 5 - 5
[10] TOO GOOD TO BE TRUE
GOODMAN, S
[J]. COLUMBIA JOURNALISM REVIEW, 1984, 22 (05) : 48 - 49

← 1 2 3 4 5 →